Free Trial

Integra LifeSciences (IART) Stock Price, News & Analysis

+0.25 (+0.93%)
(As of 03:09 PM ET)
Today's Range
50-Day Range
52-Week Range
391,916 shs
Average Volume
843,710 shs
Market Capitalization
$2.15 billion
P/E Ratio
Dividend Yield
Price Target

Integra LifeSciences MarketRank™ Stock Analysis

Analyst Rating
2.00 Rating Score
36.0% Upside
$36.80 Price Target
Short Interest
3.67% of Float Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
0.69mentions of Integra LifeSciences in the last 14 days
Based on 5 Articles This Week
Insider Trading
Proj. Earnings Growth
From $3.03 to $3.29 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.98 out of 5 stars

Medical Sector

7th out of 921 stocks

Surgical & Medical Instruments Industry

1st out of 100 stocks

IART stock logo

About Integra LifeSciences Stock (NASDAQ:IART)

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services. It also sells instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute wounds; and surgical tissue repair products for hernia, tendon, peripheral nerve repair and protection. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.

IART Stock Price History

IART Stock News Headlines

Integra LifeSciences (NASDAQ:IART) Shares Gap Up to $27.49
Integra: Q1 Earnings Snapshot
Integra LifeSciences Holdings Corporation (IART)
See More Headlines
Receive IART Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Integra LifeSciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Surgical & medical instruments
Health Care Equipment
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
11 Analysts


Net Income
$67.74 million
Pretax Margin


Sales & Book Value

Annual Sales
$1.53 billion
Cash Flow
$4.78 per share
Book Value
$20.31 per share


Free Float
Market Cap
$2.15 billion

Social Links

10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

IART Stock Analysis - Frequently Asked Questions

Should I buy or sell Integra LifeSciences stock right now?

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Integra LifeSciences in the last year. There are currently 3 sell ratings, 5 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" IART shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IART, but not buy additional shares or sell existing shares.
View IART analyst ratings
or view top-rated stocks.

What is Integra LifeSciences' stock price target for 2024?

11 equities research analysts have issued 12-month price targets for Integra LifeSciences' shares. Their IART share price targets range from $24.00 to $53.00. On average, they anticipate the company's share price to reach $36.80 in the next year. This suggests a possible upside of 36.0% from the stock's current price.
View analysts price targets for IART
or view top-rated stocks among Wall Street analysts.

How have IART shares performed in 2024?

Integra LifeSciences' stock was trading at $43.55 at the beginning of the year. Since then, IART stock has decreased by 37.9% and is now trading at $27.05.
View the best growth stocks for 2024 here

When is Integra LifeSciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, July 24th 2024.
View our IART earnings forecast

How were Integra LifeSciences' earnings last quarter?

Integra LifeSciences Holdings Co. (NASDAQ:IART) released its earnings results on Monday, May, 6th. The life sciences company reported $0.55 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.55. The life sciences company had revenue of $368.90 million for the quarter, compared to analyst estimates of $361.96 million. Integra LifeSciences had a net margin of 2.63% and a trailing twelve-month return on equity of 14.27%. The firm's quarterly revenue was down 3.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.74 EPS.

What ETFs hold Integra LifeSciences' stock?
When did Integra LifeSciences' stock split?

Integra LifeSciences shares split before market open on Tuesday, January 3rd 2017. The 2-1 split was announced on Thursday, December 22nd 2016. The newly created shares were distributed to shareholders after the closing bell on Wednesday, December 21st 2016. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

What guidance has Integra LifeSciences issued on next quarter's earnings?

Integra LifeSciences updated its FY24 earnings guidance on Monday, May, 6th. The company provided earnings per share (EPS) guidance of $3.01-3.11 for the period, compared to the consensus estimate of $3.19. The company issued revenue guidance of $1.67-1.69 billion, compared to the consensus revenue estimate of $1.62 billion.

What is Peter J. Arduini's approval rating as Integra LifeSciences' CEO?

173 employees have rated Integra LifeSciences Chief Executive Officer Peter J. Arduini on Peter J. Arduini has an approval rating of 74% among the company's employees.

What other stocks do shareholders of Integra LifeSciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Integra LifeSciences investors own include Boeing (BA), NVIDIA (NVDA), AbbVie (ABBV), Adobe (ADBE), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Intel (INTC), Marvell Technology (MRVL), Alexion Pharmaceuticals (ALXN) and Abbott Laboratories (ABT).

Who are Integra LifeSciences' major shareholders?

Integra LifeSciences' stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (8.88%), Capital Research Global Investors (7.51%), Champlain Investment Partners LLC (3.41%), Leeward Investments LLC MA (0.58%), Easterly Investment Partners LLC (0.38%) and Principal Financial Group Inc. (0.33%). Insiders that own company stock include Glenn Coleman, Jeffrey Mosebrook, Lisa Evoli, Michael J Mcbreen, Raymond G Murphy, Tru St Partnership, LP and Witte Jan De.
View institutional ownership trends

How do I buy shares of Integra LifeSciences?

Shares of IART stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Integra LifeSciences have any subsidiaries?
The following companies are subsidiares of Integra LifeSciences: ACell Inc, ACell Inc., Arkis BioSciences, Arkis Biosciences Inc., Ascension Orthopedics Inc., Ascension Orthopedics Limited, BIMECO Inc., BioD LLC, BioDlogics LLC, BioRecovery LLC, CardioDyne Inc., Cathtec Incorporated, Caveangle Limited, Codman Neuro, Confluent Surgical, Confluent Surgical Inc., Derma First Aid Products Inc., Derma Sciences, Derma Sciences Canada Inc., Derma Sciences Europe Limited, Derma Sciences Inc., EndoSolutions Inc., Fiber Imaging Technologies Inc., GMS Gesellschaft für medizinische Sondentechnik mbH, ILS Financing (Ireland) Limited, ILS Financing Corporation, ILS Services Switzerland Ltd., ILS Surgical Investments LLC, INS Sweden AB, Integra Burlington MA Inc., Integra CI Inc., Integra Canada ULC, Integra Euro Holdings Inc., Integra France Holdings SAS, Integra German Holdings GmbH, Integra GmbH, Integra Japan K.K., Integra LS (Benelux) NV, Integra LS Mexico S. DE R. L. DE C.V., Integra LifeSciences (Canada) Holdings Inc., Integra LifeSciences (Ireland) Limited, Integra LifeSciences (Shanghai) Co. Ltd., Integra LifeSciences Austria GmbH, Integra LifeSciences Brazil Ltda., Integra LifeSciences Corporation, Integra LifeSciences Enterprises LLLP, Integra LifeSciences Financing (Cyprus) Limited, Integra LifeSciences Italy S.r.l., Integra LifeSciences Middle East FZ-LLC, Integra LifeSciences Production Corporation, Integra LifeSciences Sales LLC, Integra LifeSciences Services (France) SAS, Integra LifeSciences Shared Services (Ireland) Limited, Integra LifeSciences Singapore Pte. Ltd., Integra LifeSciences Spain S.L., Integra LifeSciences Switzerland Sárl, Integra Luxtec Inc., Integra ME GmbH, Integra MicroFrance SAS, Integra NeuroSciences (International) Inc., Integra NeuroSciences Holdings (UK) Limited, Integra NeuroSciences Holdings B.V., Integra NeuroSciences Implants (France) SAS, Integra NeuroSciences Limited, Integra Neurosciences, Integra Neurosciences Pty Ltd. (AUS), Integra Neurosciences Pty Ltd. (NZ), Integra Receivables LLC, Integra Sales Inc., Integra Selector LLC, Integra Switzerland Holdings Sarl, Integra York PA Inc., IsoTis NV, IsoTis T.E. Facility B.V., J. Jamner Surgical Instruments Inc., Jarit GmbH, Kinetikos Medical, Koby Ventures II L.P. dba Metasurg, LXU Healthcare Inc. - Medical Specialty Products, MedEfficiency Inc., Medtronic Xomed Instrumentation SAS, Miltex, Minnesota Scientific Inc., Nantong Derma Medical Products Co. Ltd., Newdeal Inc., Newdeal SAS, Omni-Tract, Precise Dental Holding Corp., Precise Dental Internacional S.A. de C.V., Precise Dental Products Ltd., Precision Dental International Inc., Rebound Therapeutics, Rebound Therapeutics Corporation, Spembly Cryosurgery Limited, Spembly Medical Limited, TEI Biosciences (UK) Limited, TEI Biosciences Inc., TEI Biosciences Inc., TEI Medical Inc., TGX Medical Systems, TGX Medical Systems LLC, Tarsus Medical Inc., Tarsus Medical Inc., Tekmed Instruments S.p.A, Theken Disc, Theken Spine, and Therics.
Read More
This page (NASDAQ:IART) was last updated on 5/21/2024 by Staff

From Our Partners